ENANTA PHARMACEUTICALS INC (ENTA) Form 8-K — May 11, 2026
Enanta Pharmaceuticals, Inc. reported financial results for the fiscal quarter ended March 31, 2026. The company's total revenue was $17.2 million, a 15.6% increase from $14.9 million in the same period last year, primarily driven by higher royalty revenue from AbbVie’s MAVYRET®/MAVIRET® sales. Research and development expenses decreased to $19.4 million from $28.1 million in the prior year, a reduction of 30.7%, due to lower clinical trial expenses for RSV programs.
Key figures
- Revenue
- 17159
- Cash Position
- 227000
- Royalty Revenue
- 17159
- Interest Expense
- 3316
- Interest Expense Yoy
- 94
- Interest And Investment Income
- 2084
- Research And Development Expenses
- 19443
- General And Administrative Expenses
- 9568
Price after filing
Close on the filing date to close N calendar days later (from $15.46). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.